Calviri
calviri.com
Actively hiring
Vaccines
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$17.4M
8 rounds on record
Latest round
$785k
Venture round · Oct 2024 · 23 mo ago
Team
51-200
employees, estimated range
Grants
$300k
1 grant · CORDIS
The money's age
Due for its next round
23 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 24, 2024
Raised a round Venture round $785k · SEC Form D
Sep 6, 2024
Raised a round Venture round $150k · SEC Form D
Oct 4, 2023
Board appointment Jeffrey Le Benger, Director · SEC Form D
Sep 20, 2023
Raised a round Venture round $650k · SEC Form D
Nov 12, 2021
New executive Marc Wolff, Executive Officer, Director · SEC Form D
Oct 28, 2021
Raised a round Venture round $11.1M · SEC Form D
Oct 20, 2020
Board appointment Michael McCallister, Director · SEC Form D
Sep 24, 2020
Raised a round Venture round $2.4M · SEC Form D
Sep 24, 2020
Raised a round Venture round $430k · SEC Form D
Sep 12, 2019
Won a grant $300k · CORDIS
Dec 20, 2018
Raised a round Venture round $1.9M · SEC Form D
2015
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2024 | $785k | — | SEC Form D |
| Venture round | Sep 2024 | $150k | — | SEC Form D |
| Venture round | Sep 2023 | $650k | — | SEC Form D |
| Venture round | Oct 2021 | $11.1M | — | SEC Form D |
| Venture round | Sep 2020 | $430k | — | SEC Form D |
| Venture round | Sep 2020 | $2.4M | — | SEC Form D |
| Grant | Sep 2019 | $300k | — | CORDIS |
| Venture round | Dec 2018 | $1.9M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Calviri, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Stephen JohnstonExecutive Officer, DirectorSEC Form D
Marc WolffExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Positioned to deliver revolutionary off-the-shelf cancer vaccines. OUR CORE MISSION.
CREATE Medicines is pioneering in vivo immune cell programming with RNA powered, LNP delivered CAR therapies – unlocking scalable…
Gamgee is developing personalised mRNA vaccines as a cancer treatment for dogs, built from each dog’s tumour. See how it works with vets…
TareBio develops vaccines for cancer and infectious diseases by decoding immune responses to engineer targeted antigens.
The Loomia Electronic Layer (LEL) is an award-winning, soft and flexible circuit that makes impossible products possible. Use the LEL for…
Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases…
People
Stephen Johnston
Executive Officer, Director
Marc Wolff
Executive Officer, Director
George Poste
Director
Kathryn Sykes
Director
Neal Woodbury
Director
Jacque Sokolov
Director
Anna Barker
Director
Michael Chambers
Director
Michael McCallister
Director
Jeff Le Benger
Director
Jeffrey Le Benger
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Phoenix
United States
HQ
50-200 est. staff
850 North 5th Street, Phoenix, AZ, 85004-2289, US
Financials
Total raised
$17.7M
Latest round
Venture - Series Unknown
Funding rounds
8
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $785k | Details |
| Venture - Series Unknown | 2024 | $150k | Details |
| Venture - Series Unknown | 2023 | $650k | Details |
| Venture - Series Unknown | 2021 | $11.1M | Details |
| Venture - Series Unknown | 2020 | $430k | Details |
| Venture - Series Unknown | 2020 | $2.4M | Details |
| Grant | 2019 | $300k | Details |
| Venture - Series Unknown | 2018 | $1.9M | Details |